Crohn's disease

[Tiziana Life Sciences Ltd.] Tiziana Life Sciences announced initiation of a Phase Ib clinical trial to evaluate orally administered enteric-coated capsules of foralumab in patients with mild-to-moderate Crohn's Disease.

[AbbVie, Inc.] AbbVie announced that it has submitted an application to the US FDA seeking approval for risankizumab-rzaa, an interleukin-23 inhibitor, for the treatment of patients 16 years and older with moderate to severe Crohn's disease.

[Molecular and Cellular Endocrinology] The authors highlight the role of fatty acids in maintenance of intestinal and immune homeostasis and supports the supplementation of fatty acids as a promising adjunctive treatment for Crohn's disease.

[Molecular Therapy] VBIT-12 treatment of cultured colon cells inhibited the DSS-induced VDAC1 overexpression, oligomerization, and apoptosis.

[Biomedicine & Pharmacotherapy] The authors examine the implications of lymphatic changes in IBD pathogenesis related to immune cells, gut microbiota, intestinal and mesenteric epithelial barrier integrity, and progression to colorectal cancer.

[Journal of Crohns & Colitis] Effects of intestinal epithelial cells transfected with metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) lentiviruses and Smart Silencer, on monolayer permeability and apical junction complex proteins were analyzed.